AI-curated PubMed digests

Your Weekly Medical Digest — Only the Latest Publications.

Stay current with the medical literature that matters to your field. xxcode helps you find, review, and listen to important new research without spending hours searching.

Start for freeHow it works

Join 5,000+ physicians, residents, and medical students

Start free · No credit card required

  • Audio + text
  • Clinical research
  • Evidence-focused
  • Open access
Digest for Oct 21, 2026 – Oct 27, 2026
12 papersUpdated recently
Clinical Research

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

N Engl J MedOct 15, 2026

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

Key findings

  • Estimated 24-month event-free survival was 86% with ponatinib–blinatumomab versus 67% with imatinib–chemotherapy (P<0.001).
  • Survival with no measurable residual disease was 68% in the intervention group and 42% in the control group.
  • Complete hematologic response at the end of induction occurred in 94% versus 79%, respectively.
Specialty: HematologyView full text
Live · Publications from PubMed counted over the past 7 days

Why xxcode

Less searching. More knowing.

Every week, xxcode automatically finds and organizes new literature around your specialty and preferences.

Only the last 7 days

Fresh literature first — without digging through old archives.

Evidence-focused

Trials, meta-analyses, and systematic reviews are prioritized.

Read or listen

Read a concise digest or listen to the audio version when it suits you.

Tuned to your field

Choose your specialties once, and each digest follows your interests.

How it works

From preferences to digest — automatically.

xxcode keeps you current without adding hours to your week. Just three simple steps.

  1. 01

    Choose your interests

    Select your specialties, interests, and preferred reading or listening format.

  2. 02

    We find what matters

    xxcode follows new literature in your selected fields and prioritizes publications likely to be most relevant.

  3. 03

    Your digest is ready

    Receive a weekly digest you can quickly scan, read in full, or listen to whenever it suits you.

Trending Now

See what clinicians are reading

Explore recent medical literature without an account. Open any article, then create your personalized digest whenever you are ready.

View all Trending
AllClinical ResearchCase Reports
FeaturedClinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

N Engl J MedOct 15, 2026

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

Why it matters

The trial provides randomized evidence that a chemotherapy-free combination of a tyrosine kinase inhibitor and immunotherapy can improve event-free survival compared with an imatinib–chemotherapy regimen in adults with…

Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary
Clinical ResearchHematology

Prognostic value of measuring LSC frequency in AML: a systematic review and meta-analysis.

This systematic review and reconstructed individual patient data meta-analysis assessed whether leukemia stem cell (LSC) measurements predict outcomes in patients with acute myeloid leukemia at diagnosis or in…

Blood AdvOct 15, 2026Read summary
Clinical ResearchEmergency Medicine

A multifaceted intervention to increase bystander CPR rates after out-of-hospital cardiac arrest in France: a stepped-wedge, cluster-randomised, controlled trial.

This stepped-wedge, cluster-randomised controlled trial assessed a coordinated intervention to increase bystander CPR before EMS arrival among adults with non-traumatic out-of-hospital cardiac arrest in France.

Lancet Public HealthOct 21, 2026Read summary
View all TrendingCreate your personalized digest
Learning that Gives Back.

Learning that Gives Back.

At xxcode, we believe learning can create impact beyond medicine. We are committed to directing a portion of future subscription revenue toward helping homeless animals with food, veterinary care, medications, and other essential needs. Until subscription revenue begins, selected initiatives may be funded directly by the xxcode team. Follow our Impact page to see the work, stories, and support made possible along the way.

See our impact →

Stay current in minutes, not hours.

Your personalized weekly digest, delivered and ready every week.

Start for free